NYSE:BCR C.R. Bard (BCR) Stock Price, News & Analysis → Tech GIANT’s Plans to Revolutionize Crypto… (From Crypto 101 Media) (Ad) Free BCR Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Share Share Today's Range$331.24▼$331.2450-Day Range N/A52-Week Range$222.42▼$337.73VolumeN/AAverage Volume679,456 shsMarket CapitalizationN/AP/E Ratio21.91Dividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Get C.R. Bard alerts: Email Address Ad Crypto 101 MediaTech GIANT’s Plans to Revolutionize Crypto…A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the plans in these leaked internal documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, XRP and MORE… The coupling of gaming and cryptocurrency could absolutely transform digital finance as we know it in 2024. Claim your free seat by clicking here now. About C.R. Bard Stock (NYSE:BCR)C. R. Bard, Inc. (Bard) is engaged in designing, manufacturing, packaging, distribution and sale of medical, surgical, diagnostic and patient care devices. The Company operates through the manufacture and sale of medical devices segment. It sells a range of products to hospitals, individual healthcare professionals, extended care facilities and alternate site facilities on a global basis. Its vascular products cover a range of minimally invasive devices for the treatment of peripheral vascular disease and end-stage renal disease. Its urology products include basic urology drainage products, fecal and urinary continence products, urological specialty products and Targeted Temperature Management products. Its oncology products cover a range of devices used in the treatment and management of various cancers, and other diseases and disorders. Its surgical specialty products include implanted patches and fixation devices for hernia and soft tissue repairs.Read More Ad Crypto 101 MediaTech GIANT’s Plans to Revolutionize Crypto…A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the plans in these leaked internal documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, XRP and MORE… The coupling of gaming and cryptocurrency could absolutely transform digital finance as we know it in 2024. Claim your free seat by clicking here now. BCR Stock News HeadlinesApril 30, 2024 | msn.comBard College professor awarded research grant for more than $375kApril 13, 2024 | sports.yahoo.comRockies relief pitcher Daniel Bard needs elbow surgery, will miss rest of seasonMay 7, 2024 | Crypto 101 Media (Ad)Tech GIANT’s Plans to Revolutionize Crypto…A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the plans in these leaked internal documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, XRP and MORE… The coupling of gaming and cryptocurrency could absolutely transform digital finance as we know it in 2024. April 13, 2024 | msn.comDaniel Bard Won't Return In 2024April 12, 2024 | msn.comRockies reliever Daniel Bard to undergo season-ending flexor tendon surgeryApril 12, 2024 | msn.comRockies RHP Daniel Bard to have season-ending elbow surgeryApril 12, 2024 | msn.comRockies RHP Daniel Bard needs elbow surgery, will miss rest of seasonApril 10, 2024 | msn.comDealer Gavin Brown Donates His Archive to Bard College's Curatorial Studies ProgramMay 7, 2024 | Crypto 101 Media (Ad)Tech GIANT’s Plans to Revolutionize Crypto…A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the plans in these leaked internal documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, XRP and MORE… The coupling of gaming and cryptocurrency could absolutely transform digital finance as we know it in 2024. April 10, 2024 | msn.comBard Prison Initiative gets $4.5M in federal fundingApril 2, 2024 | msn.comInside a completely free program at Bard MicrocollegeMarch 29, 2024 | msn.comDaniel Bard Begins Season On Injured ListFebruary 20, 2024 | msn.comWhat is Google Bard? Everything you need to know about the ChatGPT rivalFebruary 14, 2024 | msn.comDaniel Bard will be sidelined for five to seven weeks after suffering a tear in his meniscus.February 13, 2024 | msn.comRockies reliever Daniel Bard will have surgery to repair a torn meniscus in left kneeFebruary 8, 2024 | msn.comGoogle is rebranding its Bard AI service as Gemini. Here's what it means.February 8, 2024 | msn.comGoogle rebrands Bard to Gemini, now available for the first time in mobileFebruary 8, 2024 | msn.comGoogle rebrands Bard to Gemini – and Geminis everywhere are offendedFebruary 7, 2024 | msn.comBard is becoming Gemini and getting a paid versionFebruary 7, 2024 | msn.comHow to use Google Bard: Everything you should knowFebruary 5, 2024 | msn.comGoogle Bard to be rebranded as Gemini – reportsFebruary 5, 2024 | msn.comGoogle Bard's rebranding to Gemini might just be around the cornerFebruary 4, 2024 | msn.comBard image creator is hereFebruary 2, 2024 | msn.comFilm, health care, and Bard early college: New high schools coming to Brooklyn and QueensFebruary 1, 2024 | msn.comGoogle Bard adds image generationFebruary 1, 2024 | msn.comBard generates photos now, finallyJanuary 31, 2024 | msn.comGoogle confirms you’ll need to pay for Bard Advanced — here’s what it can doSee More Headlines Receive BCR Stock News and Ratings via Email Sign-up to receive the latest news and ratings for C.R. Bard and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings10/25/2017Today5/07/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSE SectorN/A Industry N/A Sub-IndustryHealth Care Equipment Current SymbolNYSE:BCR CUSIP06738310 CIK9892 Webwww.crbard.com Phone+1-908-2778000FaxN/AEmployeesN/AYear FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E Ratio21.91 Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable BetaN/A These 7 Stocks Will Be Magnificent in 2024With average gains of 150% since the start of 2023, now is the time to give these stocks a look and pump up your 2024 portfolio.Get This Free Report Key ExecutivesTimothy M. Ring (Age 59)Chairman of the Board, Chief Executive Officer John H. Weiland (Age 61)President, Vice Chairman of the Board, Chief Operating Officer James C. Beasley (Age 53)Group President Timothy P. Collins (Age 56)Group President John P. Groetelaars (Age 50)Group President Christopher S. Holland (Age 50)Chief Financial Officer, Senior Vice President Samrat S. Khichi (Age 49)Senior Vice President, General Counsel, Secretary John A. DeFord Ph.D. (Age 55)Senior Vice President - Science, Technology and Clinical Affairs Frank Lupisella Jr. (Age 56)Vice President, Controller Betty D. Larson (Age 41)Vice President - Human Resources More Executives BCR Stock Analysis - Frequently Asked Questions How were C.R. Bard's earnings last quarter? C.R. Bard Inc (NYSE:BCR) announced its quarterly earnings results on Wednesday, October, 25th. The medical instruments supplier reported $3.02 earnings per share for the quarter, beating the consensus estimate of $2.96 by $0.06. The medical instruments supplier had revenue of $989.80 million for the quarter, compared to the consensus estimate of $990.64 million. C.R. Bard's revenue was up 5.1% on a year-over-year basis. During the same period last year, the business earned $2.64 EPS. Is C.R. Bard a good dividend stock? C.R. Bard (NYSE:BCR) pays an annual dividend of $0.78 per share and currently has a dividend yield of 0.00%. The dividend payout ratio is 5.16%. This payout ratio is at a healthy, sustainable level, below 75%. Read our dividend analysis for BCR. What other stocks do shareholders of C.R. Bard own? Based on aggregate information from My MarketBeat watchlists, some companies that other C.R. Bard investors own include Abbott Laboratories (ABT), Becton, Dickinson and Company (BDX), Medtronic (MDT), Intuitive Surgical (ISRG), Johnson & Johnson (JNJ), AbbVie (ABBV), Baxter International (BAX), Boston Scientific (BSX), Aflac (AFL) and Stryker (SYK). This page (NYSE:BCR) was last updated on 5/7/2024 by MarketBeat.com Staff From Our PartnersThe Department of Defense Has a New Drone ContractorThe Tomorrow InvestorThe A.I. story nobody is telling you (Read ASAP)TradeSmithCould Your Accounts Be Frozen?Allegiance GoldThe asset beating inflation by 4xColonial MetalsElon Musk Secret Crypto Plot ExposedCrypto 101 MediaHe Is Giving Away BitcoinCrypto Swap ProfitsThe 2024 Gold Rush: Unleashing Market PotentialPriority GoldPOTUS in ‘25 Not Biden/Trump, ButThe Freeport Society Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding C.R. Bard Inc Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
